Pharmacokinetics of ß-d-N4-hydroxycytidine, the parent nucleoside of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection

Richard Fitzgerald, Laura Dickinson, Laura Else, Tom Fletcher, Colin Hale, Alieu Amara, Lauren Walker, Sujan Dilly Penchala, Rebecca Lyon, Victoria Shaw, William Greenhalf, Katie Bullock, Lara Lavelle-Langham, Helen Reynolds, Wendy Painter, Wayne Holman, Sean Ewings, Gareth Griffiths, Saye Khoo

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at sites of SARS-CoV-2 transmission in twelve patients enrolled in AGILE CST-2 (NCT04746183). Saliva, nasal and tear concentrations were 3, 21 and 22% that of plasma. Saliva and nasal NHC concentrations were significantly correlated with plasma (p<0.0001).

Original languageEnglish
Pages (from-to)e525-e528
JournalClinical Infectious Diseases
Volume75
Issue number1
Early online date10 Mar 2022
DOIs
Publication statusPublished - 1 Jul 2022

Keywords

  • COVID-19
  • molnupiravir
  • nonplasma
  • pharmacokinetics
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'Pharmacokinetics of ß-d-N4-hydroxycytidine, the parent nucleoside of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection'. Together they form a unique fingerprint.

Cite this